Drug Profile
Research programme: ACE modulators - Boehringer Ingelheim
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ark Therapeutics
- Developer Boehringer Ingelheim
- Class
- Mechanism of Action ACE modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Germany
- 16 Mar 2011 Preclinical development is ongoing in Germany
- 14 May 2010 Preclinical development is ongoing in Germany